GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of OCX
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Red day on Friday for OncoCyte Corp
(Updated on Apr 19, 2024)

Sell candidate since Apr 17, 2024 Loss -3.47% PDF

The OncoCyte Corp stock price fell by -2.34% on the last day (Friday, 19th Apr 2024) from $2.56 to $2.50. It has now fallen 3 days in a row. During the last trading day the stock fluctuated 2.41% from a day low at $2.49 to a day high of $2.55. The price has fallen in 6 of the last 10 days and is down by -13.79% for this period. Volume has increased on the last day by 13 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 50 thousand shares were bought and sold for approximately $125.39 thousand.

The stock has broken the wide and falling short-term trend down. Firstly a stronger fallrate is indicated, but false breaks and "sell-off" may occur. However, a further fall is realistic and any reactions back to the breaking point ($2.51) are considered to be a "second chance" to get out. According to the fan-theory $2.14 will represent the new bottom line of the next trend, but it is far too early to say this for certain.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

OCX Signals & Forecast

There are few to no technical positive signals at the moment. The OncoCyte Corp stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $2.66 and $2.92. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Tuesday, April 16, 2024, and so far it has fallen -9.09%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). OncoCyte Corp gained volume on the last day, but on falling prices. In technical terms, this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-offs".

Support, Risk & Stop-loss for OncoCyte Corp stock

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.0600 between high and low, or 2.41%. For the last week, the stock has had daily average volatility of 6.27%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (OCX) For The Upcoming Trading Day Of Monday 22nd

For the upcoming trading day on Monday, 22nd we expect OncoCyte Corp to open at $2.51, and during the day (based on 14 day Average True Range), to move between $2.35 and $2.65, which gives a possible trading interval of +/-$0.153 (+/-6.13%) up or down from last closing price. If OncoCyte Corp takes out the full calculated possible swing range there will be an estimated 12.26% move between the lowest and the highest trading price during the day.

With no support below and resistance from accumulated volume @ $2.53, some $0.0300 (1.20%) from the current price of $2.50, our system finds the risk reward not very attractive.

Is OncoCyte Corp stock A Buy?

OncoCyte Corp holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -4.671 Sell Candidate Unchanged

Predicted Opening Price for OncoCyte Corp of Monday, April 22, 2024

Fair opening price April 22, 2024 Current price
$2.51 ( 0.533%) $2.50

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for OCX

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 2.57 2.93 %
R2 2.55 2.02 %
R1 2.54 1.45 %
Current price: 2.50
Support S1 2.49 -0.383 %
S2 2.48 -0.95 %
S3 2.45 -1.87 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 2.75 10.00 %
R2 2.71 8.40 %
R1 2.53 1.20 %
Current price 2.50
Support S1 0 .
S2 0 .
S3 0 .

FAQ

What is the symbol for OncoCyte Corp Stock and on which exchange is it traded?
The symbol for OncoCyte Corp is OCX and it is traded on the NYSE (New York Stock Exchange).

Should I buy or sell OncoCyte Corp Stock?
OncoCyte Corp holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

How to buy OncoCyte Corp Stock?
OncoCyte Corp Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy OncoCyte Corp Stock.

What's the current price of OncoCyte Corp Stock?
As of the end of day on the 2024-04-19, the price of an OncoCyte Corp (OCX) share was $2.50.

What is the 52-week high and low for OncoCyte Corp Stock?
The 52-week high for OncoCyte Corp Stock is $4.61 and the 52-week low is $0.190.

What is the market capitalization of OncoCyte Corp Stock?
As of the 2024-04-19, the market capitalization of OncoCyte Corp is 21.179M.

When is the next earnings date for OncoCyte Corp?
The upcoming earnings date for OncoCyte Corp is May 09, 2024.
Click to get the best stock tips daily for free!

About OncoCyte Corp

OncoCyte OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support... OCX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT